company background image
ALM logo

Almirall BME:ALM Stock Report

Last Price

€10.31

Market Cap

€2.2b

7D

3.6%

1Y

28.9%

Updated

16 Mar, 2025

Data

Company Financials +

Almirall, S.A.

BME:ALM Stock Report

Market Cap: €2.2b

ALM Stock Overview

Operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. More details

ALM fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends1/6

Rewards

Trading at 51.7% below our estimate of its fair value

Earnings are forecast to grow 35.42% per year

Became profitable this year

Risk Analysis

Large one-off items impacting financial results


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Almirall, S.A. Competitors

Laboratorios Farmaceuticos Rovi

BME:ROVI

€2.7b

Faes Farma

BME:FAE

€1.0b

Laboratorio Reig Jofre

BME:RJF

€209.8m

Labiana Health

BME:LAB

€21.8m

Price History & Performance

Summary of share price highs, lows and changes for Almirall
Historical stock prices
Current Share Price€10.31
52 Week High€10.39
52 Week Low€7.85
Beta0.37
1 Month Change14.43%
3 Month Change22.52%
1 Year Change28.88%
3 Year Change-15.70%
5 Year Change4.67%
Change since IPO-31.27%

Recent News & Updates

Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are

Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Recent updates

Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are

Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear

Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Is Almirall (BME:ALM) A Risky Investment?

May 16
Is Almirall (BME:ALM) A Risky Investment?

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Mar 29
Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Jan 04
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01
An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14
Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01
Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06
Is Almirall (BME:ALM) Using Too Much Debt?

Shareholder Returns

ALMES PharmaceuticalsES Market
7D3.6%-1.0%-2.1%
1Y28.9%-10.1%19.3%

Return vs Industry: ALM exceeded the Spanish Pharmaceuticals industry which returned -10.1% over the past year.

Return vs Market: ALM exceeded the Spanish Market which returned 19.3% over the past year.

Price Volatility

Is ALM's price volatile compared to industry and market?
ALM volatility
ALM Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement3.8%
Market Average Movement3.4%
10% most volatile stocks in ES Market6.8%
10% least volatile stocks in ES Market0.7%

Stable Share Price: ALM has not had significant price volatility in the past 3 months compared to the Spanish market.

Volatility Over Time: ALM's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19432,026Carlos Gallardo Piquéwww.almirall.com

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology.

Almirall, S.A. Fundamentals Summary

How do Almirall's earnings and revenue compare to its market cap?
ALM fundamental statistics
Market cap€2.20b
Earnings (TTM)€10.15m
Revenue (TTM)€990.63m

216.9x

P/E Ratio

2.2x

P/S Ratio

Is ALM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALM income statement (TTM)
Revenue€990.63m
Cost of Revenue€240.43m
Gross Profit€750.20m
Other Expenses€740.05m
Earnings€10.15m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Jul 25, 2025

Earnings per share (EPS)0.048
Gross Margin75.73%
Net Profit Margin1.02%
Debt/Equity Ratio23.4%

How did ALM perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

396%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 09:33
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Almirall, S.A. is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elena FernándezAhorro Corporación
Guilherme SampaioBanco BPI, S.A.
Álvaro Arístegui EchevarríaBanco de Madrid S.A.U.